Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZGN-440 sterile diluent · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| ZGN-440 sterile diluent | PLACEBO_COMPARATOR | Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks. |
| ZGN-440 for injectable suspension | EXPERIMENTAL | Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks. |
| 1.2 mg ZGN-440 for injectable suspension | EXPERIMENTAL | Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks. |
| 1.8 mg ZGN-440 for injectable suspension | EXPERIMENTAL | Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks. |
| Name | Type | Description |
|---|---|---|
| ZGN-440 sterile diluent | DRUG | ZGN-440 sterile diluent/placebo |
| ZGN-440 for injectable suspension | DRUG | - |
| 1.2 mg ZGN-440 for injectable suspension | DRUG | 1.2 mg beloranib |
| 1.8 mg ZGN-440 for injectable suspension | DRUG | 1.8 mg beloranib |
Inclusion Criteria: * Obesity as a consequence of acquired anatomical hypothalamic damage as evidenced by BMI ≥30 and ≤60 kg/m2 * Greater than 6 months post-treatment, including chemotherapy, surgery or radiation with resulting injury to the hypothalamus and/or the pituitary * Stable body weight fo...
Top 20 of 32 competitors
ZGN-440 sterile diluent is an investigational small molecule being developed by Larimar Therapeutics, Inc. (LRMR) for the treatment of obesity. It is currently in Phase 2 clinical development. The drug has been studied in patients with obesity and overweight conditions, including those with Prader-Willi Syndrome and hypothalamic injury.
ZGN-440 sterile diluent is being developed by Larimar Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol LRMR. The company is conducting clinical trials to evaluate the drug's efficacy, safety, and pharmacokinetics in obese patients.
ZGN-440 sterile diluent is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, but the drug remains in clinical development and is not yet available for commercial use.
ZGN-440 sterile diluent has been studied in two completed Phase 2 clinical trials. NCT01818921 evaluated the drug in obese subjects with Prader-Willi Syndrome, enrolling 17 participants in the United States. NCT02063295 assessed the drug in obese subjects with hypothalamic injury, enrolling 14 participants in the United States and Australia.
ZGN-440 sterile diluent is associated with the drug beloranib, as indicated by the clinical trial titles for NCT01818921 and NCT02063295, which both reference beloranib. The trials were conducted to evaluate the efficacy, safety, and pharmacokinetics of beloranib in obese patient populations.